跳至主要内容
临床试验/NCT00182260
NCT00182260已完成不适用

ELVIS (Esophagitis-Laparoscopy Versus Inhibitors of Secretion) A Randomized Controlled Trial of Laparoscopic Nissen Fundoplication (LNF) Versus Omeprazole for Treatment of Patients With Chronic Gastro-Esophageal Reflux Disease (GERD)

McMaster University1 个研究点 分布在 1 个国家目标入组 216 人开始时间: 2000年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
216
试验地点
1
主要终点
GERD Symptom Scale

研究概览

简要总结

LNF is an effective intervention in the management of patients with chronic GERD requiring maintenance therapy. LNF is cost-effective compared with long-term medical therapy.

LNF is more effective than maximum medical therapy in control of respiratory symptoms and complications of GERD.

详细描述

GERD encompasses a variety of symptoms and pathological findings caused by the reflux of gastric contents into the esophagus although symptoms and pathology may occur independently of each other. GERD usually presents with typical symptoms of retrosternal burning (heartburn) with or without chest pain and regurgitation of gastric contents into the back of the mouth. However, symptoms often occur in the absence of abnormalities associated with GERD, such as esophageal erosions, ulceration, stricturing or Barrett's esophagus. There is no clear correlation between symptoms and the histological features of GERD. Less prevalent manifestations of GERD include the geneses of dental erosions and respiratory disease including aspiration pneumonia, asthma, chronic laryngitis. Most often, GERD is due to excessive reflux of gastric contents into the esophagus rather than gastric acid hypersecretion. Reflux is caused by an increase in the frequency of inappropriate transient relaxations of the lower esophageal sphincter (LES). In most patients, basal resting LES pressure is normal although LES hypotonia, reduced esophageal body contractility and the presence of a hiatus hernia may exacerbate reflux or reduce esophageal clearance. Impaired esophageal mucosal resistance can increase the potential for esophageal damage. Bile acids and pancreatic enzymes have been implicated in the pathogenesis of GERD but it is generally accepted that the major causes of esophageal symptoms and injury are gastric acid and pepsin, which are active only at low ambient pH. Severity of esophagitis and of reflux symptoms correlate well with the duration of esophageal acid exposure with clear correlation between acid secretory inhibition and esophagitis healing rates for any given drug. On this basis, treatment for GERD has been directed towards:

Minimization of potential precipitating factors by lifestyle modifications such as weight loss, small meals and, avoidance of alcohol and tobacco.

Improving LES pressure, esophageal clearance and gastric emptying, using prokinetic agents.

Neutralization of acid in the stomach or esophagus, using antacids. Reduction of acid secretion, using histamine receptor antagonists(H2RAs) or PPI's.

Surgical prevention of gastro-esophageal reflux by fundoplication. In practice, the latter two approaches are the most successful for patients with more severe GERD and PPI's have proven more efficacious than H2RAs.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female GERD patients aged 18-70 years with GERD symptoms.
  • Prior long-term treatment with PPI with minimum duration of 1 year with expected future duration of at least 2 more years.
  • Controlled on 20-40mg/day maintenance PPI therapy prior to study, defined as GERD symptom score<18 and score of 70 or more on 1-100 Global Rating Scale at screening (on medication).
  • Increase in GERD symptom score>=15 points at baseline (off omeprazole).
  • GERD symptom score>=18 at baseline (off omeprazole).
  • Percent acid reflux in 24hr 4% at baseline (off omeprazole).
  • Positive Bernstein test at baseline.
  • Willingness to adhere to randomized treatment with availability for 3 years of follow-up.
  • Ability to answer self and interviewer-administered questions in English.
  • Signed informed consent.

排除标准

  • Aperistaltic esophagus.
  • Severe cardiac, respiratory, hematologic or other disease constituting an unacceptable surgical risk in the investigator's opinion.
  • Previous gastric, esophageal or anti-reflux surgery.
  • History of malignancy within the last year with the exception of basal cell carcinoma.
  • Pregnancy or an intention to become pregnant in the following year.

研究组 & 干预措施

Proton Pump Inhibitor

Active Comparator

Patients randomized to medical therapy received optimized treatment with PPI using a standardized management protocol based on best evidence and published guidelines.

干预措施: Proton Pump Inhibitors (Drug)

Laparoscopic Nissen Fundoplication

Active Comparator

Surgical patients underwent LNF using previously published technique.

干预措施: Laparoscopic Nissen Fundoplication (Procedure)

结局指标

主要结局

GERD Symptom Scale

Symptom-free Day Measurement

Cost Measurement

次要结局

  • 24-hour pH
  • Economic Analysis
  • Endoscopy
  • Esophageal manometry
  • Health related quality of life (SF-36)
  • Health Utility Index
  • Respiratory function, airways hypersensitivity and inflammation and microaspiration

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Mehran Anvari

Principal Investigator

McMaster University

研究点 (1)

Loading locations...

相似试验